Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia.
about
Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivoRedox-directed cancer therapeutics: molecular mechanisms and opportunitiesA new view of carcinogenesis and an alternative approach to cancer therapyExpression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpretedDichloroacetate (DCA) as a potential metabolic-targeting therapy for cancerTargeting Cancer Metabolism - Revisiting the Warburg EffectsPathophysiological mechanisms of death resistance in colorectal carcinomaTargeted Therapies in Adult B-Cell MalignanciesOvarian clear cell carcinoma meets metabolism; HNF-1β confers survival benefits through the Warburg effect and ROS reductionThe Efficacy of Ketogenic Diet and Associated Hypoglycemia as an Adjuvant Therapy for High-Grade Gliomas: A Review of the LiteratureThe three-layer concentric model of glioblastoma: cancer stem cells, microenvironmental regulation, and therapeutic implicationsCancer cell metabolism: implications for therapeutic targetsActivation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer.Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing.Killing hypoxic cell populations in a 3D tumor model with EtNBS-PDTGlucose is a key driver for GLUT1-mediated nanoparticles internalization in breast cancer cellsPFKFB3 Regulates Oxidative Stress Homeostasis via Its S-Glutathionylation in CancerMolecular Analysis by Gene Expression of Mitochondrial ATPase Subunits in Papillary Thyroid Cancer: Is ATP5E Transcript a Possible Early Tumor Marker?Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer CellsA switching mechanism in doxorubicin bioactivation can be exploited to control doxorubicin toxicityStructure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effectQuantitative proteomic and interaction network analysis of cisplatin resistance in HeLa cellsNovel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapyINMAP overexpression inhibits cell proliferation, induces genomic instability and functions through p53/p21 pathwaysDifferentiate or Die: 3-Bromopyruvate and Pluripotency in Mouse Embryonic Stem CellsA Biochemical Approach to Understand the Pathogenesis of Advanced Pulmonary Arterial Hypertension: Metabolomic Profiles of Arginine, Sphingosine-1-Phosphate, and Heme of Human LungCombination delivery of Adjudin and Doxorubicin via integrating drug conjugation and nanocarrier approaches for the treatment of drug-resistant cancer cellsCeramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemiaA self referencing platinum nanoparticle decorated enzyme-based microbiosensor for real time measurement of physiological glucose transport.In vitro optimization of EtNBS-PDT against hypoxic tumor environments with a tiered, high-content, 3D model optical screening platform.Mapping the extracellular and membrane proteome associated with the vasculature and the stroma in the embryoGenomic and oncoproteomic advances in detection and treatment of colorectal cancerMitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate.Silencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth In Vivo.Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2.Impact of Autoantibodies against Glycolytic Enzymes on Pathogenicity of Autoimmune Retinopathy and Other Autoimmune DisordersTetravalent antibody-scTRAIL fusion proteins with improved properties.Modeling core metabolism in cancer cells: surveying the topology underlying the Warburg effect.Analyzing the regulation of metabolic pathways in human breast cancer.Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition.
P2860
Q21195224-FAC2BD28-AA6B-4623-8F11-C1B7B2BCCCACQ24645584-8E8BF4F9-4C6F-409E-A691-DC67C0D1B453Q24650249-F2D2D379-86DE-4C47-A1A7-E7DE79535A0FQ24652381-84E0A600-19E4-4D18-B408-A3B23D3E8364Q24652941-67C66C57-8129-4CC8-A6DC-7078DA2F0CFBQ26738876-0D11D39A-F528-4BF4-BBF4-96ACF56AD021Q26778007-692AE27F-86CA-4013-BB34-63761342C6C5Q26783195-A7C56777-ED91-4006-A9A7-67ECFA3DD5B7Q26786610-0765FB08-7E42-42D2-8282-8146E887072DQ26800604-8FF6D21A-4123-4B12-9562-AE4C99A7574EQ26829663-7DDF6D82-D294-48D0-B54D-38EE7810AF12Q27013632-1918D236-BA2C-4B3D-B78B-94CE0889E971Q27308683-409D0C82-5B74-4352-999B-4BDC5523553AQ27317158-101CF8EC-48ED-496B-87E2-461F894CB573Q27324380-D3FCDA9F-9E08-4166-9221-677272D6E3CFQ27345982-07746870-74BD-4E03-83F4-68D3791607CCQ27680730-43D6B881-2C23-4F77-AD4A-212A5623ED64Q28263577-54D453DA-7D34-44AA-90BD-A0F7FFE5CBE4Q28391040-1F59594F-ADA2-4DB3-9A04-222CD0CF1944Q28477095-57C0300C-E323-47E6-919B-052B7EF3764FQ28477166-9176807F-D4DA-4EAB-8944-2581CE5C55C3Q28478299-50937C8F-EDBD-4202-BD2C-F5ABFDEF9B9EQ28483560-C03C8138-3BA2-457A-96CC-B02A2CE84D17Q28543171-ED5F9AE9-477D-4C40-9D6F-D58B6B4CA2BAQ28547207-3568F89C-DF4C-490A-B5E3-FC6D241BB389Q28547572-FE952F18-090E-43BB-A2FE-5350B239D2C3Q28834339-F8F9F8EC-6A56-48AA-BFBA-66FD62F6436FQ30276873-A23C104F-735F-4653-9D2B-F2C8927088C0Q30497799-034EFDCA-4002-4511-BC0C-0DD2F6D32470Q30531713-B683C141-D663-4D1A-8C0B-F2E2E053026BQ30542280-591FEC3E-A572-417D-BDAD-05AD7A973B5EQ33425477-18D36BDF-2CA9-4D98-BF4E-09637E23A738Q33564338-972FD264-BBA4-4BAA-8BB3-0518E24B2ABDQ33570738-BF2FD506-A3CB-4594-BD5C-95588AA6564FQ33587154-4A662347-2455-4F55-82F5-C980B4E803CFQ33611455-0CB53909-22B4-4D92-A2C9-89F1EBE4D198Q33619046-CA38932D-6193-4339-B808-CFE03D31DE2EQ33682181-2322CE7F-9C64-4EE4-BCB8-6948434B2FD8Q33689986-F432042A-D9D5-4776-8536-DBA177663301Q33748081-9B7A89CD-7C26-4D8C-93E5-666B8F59DEA5
P2860
Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Inhibition of glycolysis in ca ...... espiratory defect and hypoxia.
@ast
Inhibition of glycolysis in ca ...... espiratory defect and hypoxia.
@en
Inhibition of glycolysis in ca ...... espiratory defect and hypoxia.
@nl
type
label
Inhibition of glycolysis in ca ...... espiratory defect and hypoxia.
@ast
Inhibition of glycolysis in ca ...... espiratory defect and hypoxia.
@en
Inhibition of glycolysis in ca ...... espiratory defect and hypoxia.
@nl
prefLabel
Inhibition of glycolysis in ca ...... espiratory defect and hypoxia.
@ast
Inhibition of glycolysis in ca ...... espiratory defect and hypoxia.
@en
Inhibition of glycolysis in ca ...... espiratory defect and hypoxia.
@nl
P2093
P1433
P1476
Inhibition of glycolysis in ca ...... respiratory defect and hypoxia
@en
P2093
Helene Pelicano
Jennifer S Carew
Kapil N Bhalla
Michael J Keating
Peng Huang
Rui-Hua Xu
P304
P407
P577
2005-01-01T00:00:00Z